Risk-Benefit Perspectives in COX-2 Blockade

Author(s): Susan Dabu-Bondoc , Samantha Franco .

Journal Name: Current Drug Safety

Volume 3 , Issue 1 , 2008

Become EABM
Become Reviewer

Abstract:

The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. Laboratory, epidemiological, and clinical studies have surged and continued to evaluate and understand the safety of coxibs and traditional NSAIDs. This paper reviews the scientific and clinical basis of not only the risks, but also the benefits surrounding the use COX-2 inhibitors and NSAIDs. Discussion, debate, opinions, regulatory and clinical recommendations have evolved since the unexpected emergence of cardiac thrombotic events from the use of these drugs. The evidence by which coxibs and NSAIDs can potentially attenuate or exacerbate cardiovascular disease by affecting endothelial function is assessed; and how NSAIDs and coxibs affect renal function and blood pressure is revisited. Several investigations provide insight into their mechanism and clinical application.

Keywords: COX-2 inhibition, COX-blockade, NSAIDs, coxibs, COX-2 selective inhibitor, COX-2 specific inhibitor, endothelial dysfunction, gastrointestinal toxicity

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 3
ISSUE: 1
Year: 2008
Page: [14 - 23]
Pages: 10
DOI: 10.2174/157488608783333970

Article Metrics

PDF: 12